NOK 55.60
-1.90 (-3.30%)
NOK · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PHO.OL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
19 interventional · 4 observational · 12 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Blue Light Cystoscopy With Cysview® RegistryNCT02660645observationalRate of detection of bladder malignancies | — | Recruiting | Drug: Hexaminolevulinate hydrochloride (HCL) · Device: Karl Storz D-Light C Photodynamic Diagnostic (PDD) system | Bladder Cancer | 4,400 | Dec 2028 | ≤ 864 d | 2025-12-18 |
| Exploration of Novel AI-enabled Blue Light Enhanced CystoscopyNCT07144319observationalVideo and image collection | — | Recruiting | — | Bladder Cancer, Non-muscle Invasive Bladder Cancer | 500 | Dec 2027 | ≤ 498 d | 2026-08-14 |
| Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder CancerNCT05600322results2024-10-03Number of Patients With Histology-confirmed Lesions (Ta, T1, or CIS) Who Have at Least One Such Lesion Found by Hexvix Blue Light Cystoscopy But Not by White Light Cystoscopy.Open-label · DiagnosticStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Hexaminolevulinate Hydrochloride · Device: Richard Wolf Photodynamic Diagnostic Equipment (PDD) system | Bladder Cancer | 158 | 2023-07-12actual | — | 2024-10-03 |
| A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance SettingNCT02560584results2018-07-02Proportion of Patients With Histologically Confirmed Malignancy Where Malignancy is Only Detected With Blue Light Cystoscopy With Cysview and Not White Light CystoscopyOpen-label · DiagnosticStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Hexaminolevulinate hydrochloride · Device: KARL STORZ D-Light C PDD Flexible Videoscope System | Bladder Cancer | 304 | 2017-04-05actual | — | 2018-07-02 |
| Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical NeoplasiaNCT01256424results2014-08-21Comparison of Lesion Response Rates of Three Different Doses of HAL PDT and Placebo at 3 Months After Treatment.Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: HAL 5% with illumination, HAL 1% with illumination, HAL 0.2% with illumination, Placebo ointment without illumination | Cervical Intraepithelial Neoplasia | 262 | Sep 2012actual | — | 2016-05-16 |
| Detection of Bladder Tumors After 30 Min Instillation of HexvixNCT01551407Number of lesionsOpen-label · Diagnostic | Phase 2 | Terminatedsponsor's stated reason: slow inclusion rate | Drug: Hexvix | Bladder Cancer | 38 | Jun 2012actual | — | 2012-10-25 |
| A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi-center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne VulgarisNCT01347879results2014-01-16Absolute Change From Baseline in Facial Inflammatory Lesion Count (Nodules, Papules, and Pustules).Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Visonac PDT, Vehicle cream with PDT | Acne Vulgaris | 153 | Apr 2012actual | — | 2014-01-16 |
| Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1NCT00708942results2013-04-15Complete Response RateRandomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Slow recruitment, study stopped with only 13 of 70 patients included in second part of the study | Drug: Hexaminolevulinate (HAL), Placebo, Hexaminolevulinate (HAL), Placebo | Cervical Intraepithelial Neoplasia | 83 | Jan 2012actual | — | 2013-04-24 |
| Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne PatientsNCT01160848results2014-05-20Photoactive Porphyrins LevelRandomized · Open-label | Phase 2 | Completed | Drug: Area cleaned with saline water and occluded with Tegaderm, Area cleaned with saline water, Area cleaned with Ethyl alcohol solution, Visonac left on the skin for 24 hours in facial area one, Visonac wiped off after one hour, Visonac left on the skin 24 hours in facial area two | Acne Vulgaris | 20 | Jan 2011actual | — | 2014-05-20 |
| Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURBNCT01166230results2013-11-14observationalRecurrence Free Survival | — | Completed | — | Bladder Cancer | 551 | Dec 2010actual | — | 2019-04-09 |
| Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)NCT00933543results2013-11-15Proportion of Patients With Success According to the Dichotomized IGA Scale Based on Facial Assessments 12 Weeks After the First Treatment. Success is Defined as an Improvement of at Least 2 Grades From the Baseline Score.Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Visonac PDT (MAL PDT), Vehicle cream (placebo) · Procedure: PDT | Acne Vulgaris | 107 | Mar 2010actual | — | 2013-12-11 |
| An Open-label, Single-dose, Three Period Study to Determine the Pharmacokinetic Parameters of Hexaminolevulinate (HAL) Hydrochloride After Vaginal, Enema and Intravenous Administration of Healthy Female VolunteersNCT01050309To determine the extent of systemic absorption of HAL following vaginal and enema administration compared to intravenous administration to healthy female volunteers.Non-randomized · Open-label | Phase 1 | Completed | Drug: hexaminolevulinate (HAL) | Pharmacokinetics | 8 | Dec 2009actual | — | 2010-01-15 |
| An Open Dose-finding Study of Oral Applied Hexaminolevulinate (HAL) Imaging in Patients With Suspicion or High Risk of Neoplasia in the ColonNCT01344902Determine the carcinoma- and adenoma lesion true detection rateNon-randomized · Open-label · Diagnostic | Phase 1/2 | Terminatedsponsor's stated reason: The study was stopped due to inadequate efficacy after 13 patients were evaluated. | Drug: hexaminolevulinate HCl | Colon Cancer | 13 | Oct 2009actual | — | 2013-10-23 |
| A Dose-finding Study of MAL and HAL Photodynamic Therapy of Cervical Premalignant Lesions.NCT00369018Lesion eradicationRandomized · Quadruple-masked · Treatment | Phase 1/2 | Completed | Drug: methyl aminolevulinate (MAL) and hexaminolevulinate (HAL) | Cervical Dysplasia | 96 | Jul 2009actual | — | 2010-11-30 |
| Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne VulgarisNCT00673933results2013-07-12Proportion of Patients With Moderate to Severe Hypopigmentation and Hyperpigmentation Assessed After TreatmentRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Methyl aminolevulinate (MAL) PDT | Acne Vulgaris | 20 | Dec 2008actual | — | 2013-07-12 |
| A Randomized, Comparative Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder CancerNCT00412971results2013-10-11Proportion of Patients With Histologically Confirmed Recurrence Within One 1 Year.Randomized · Open-label · Diagnostic | Phase 3 | Completed | Drug: Hexvix · Other: Standard white light cystoscopy | Bladder Cancer | 233 | Oct 2008actual | — | 2013-10-11 |
| Hexvix Photodynamic Therapy in Patients With Bladder CancerNCT01303991Number of patients with adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Other: Hexvix PDT with Karl Storz T-Light | Intermediate or High-risk Bladder Cancer | 17 | Aug 2008actual | — | 2011-02-25 |
| Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence CystoscopyNCT00233402results2013-10-11Proportion of Patients With >= 1 Ta or T1 Tumor Detected With Blue Light and Not White LightRandomized · Open-label | Phase 3 | Completed | Drug: Hexvix · Procedure: Standard white light cystoscopy | Bladder Cancer | 789 | Jul 2008actual | — | 2013-10-11 |
| Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe AcneNCT00594425results2013-08-08Proportion of Success, Defined as Improvement of at Least 2 Grades From Baseline According to the IGA Scale Based on Facial AssessmentRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Methyl aminolevulinate (MAL) PDT | Acne Vulgaris | 150 | Jul 2008actual | — | 2013-08-08 |
| Safety and Efficacy Study of Topical Methyaminlevulinate (MAL) in Subjects With Facial AcneNCT00833183To compare the number of inflammatory acne lesions according to time on the side with occlusion and the side without occlusion for subjects with facial acne vulgaris exposed to 25 J/cm2 and 37 J/cm2 of red light.Randomized · Single-masked · Treatment | Phase 2 | Completed | Drug: MAL | Acne | 44 | Jul 2008actual | — | 2009-01-30 |
| Early Detection of Polyps and Colon Cancer by Fluorescence Imaging - a Dose-finding StudyNCT00285701Non-randomized · Open-label · Diagnostic | Phase 1/2 | Completed | Drug: hexaminolevulinate | Colorectal Cancer | 38 | Nov 2007actual | — | 2010-01-15 |
| Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder CancerNCT00052637Non-randomized · Open-label · Diagnostic | Phase 3 | Completed | Drug: hexaminolevulinate · Procedure: biopsy, cystoscopy | Bladder Cancer | — | May 2002actual | — | 2013-10-23 |
| Phase I Study of HAL Formulations Applied to the Cervix in Healthy VolunteersNCT00496171observational | — | Terminated | — | Healthy | — | — | — | 2009-01-16 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19